Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk

World Journal of Hepatology

Volumn 7, Issue 13, 2015, Pages 1761-1771

  Raschi, Emanuel ^a   de Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatotoxicity; Herb; Liver damage; Predictivity; Safety; Signal

Indexed keywords

EID: 84936883076     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i13.1761     Document Type: Review

References (81)

1. Chalhoub WM, Sliman KD, Arumuganathan M, Lewis JH. Druginduced liver injury: what was new in 2013? Expert Opin Drug Metab Toxicol 2014; 10: 959-980 [PMID: 24746272 DOI: 10.1517/17425255.2014.909408]
2. O'Donnell JT, Marks DH, Danese P, O'Donnell JJ. Druginduced liver disease: primer for the primary care physician. Dis Mon 2014; 60: 55-104 [PMID: 24507900 DOI: 10.1016/j. disamonth.2013.11.002]
3. Watkins PB, Merz M, Avigan MI, Kaplowitz N, Regev A, Senior JR. The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future. Drug Saf 2014; 37 Suppl 1: S1-S7 [PMID: 25352323 DOI: 10.1007/s40264-014-0181-8]
4. Wang B, Avorn J, Kesselheim AS. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther 2013; 94: 670-677 [PMID: 23963252 DOI: 10.1038/clpt.2013.165]
5. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006; 7: 889-908 [PMID: 16981848]
6. Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf 2013; 36: 183-197 [PMID: 23377696 DOI: 10.1007/s40264-013-0018-x]
7. Avigan MI. DILI and drug development: a regulatory perspective. Semin Liver Dis 2014; 34: 215-226 [PMID: 24879985 DOI: 10.1055/s-0034-1375961]
8. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015; 89: 327-334 [PMID: 25618544 DOI: 10.1007/s00204-015-1456-2]
9. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522 [PMID: 20486732 DOI: 10.2165/11535340-000000000-00000]
10. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425, 1425.e1-3, quiz e19-20 [PMID: 23419359 DOI: 10.1053/j.gastro.2013.02.006]
11. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455 [PMID: 12143055]
12. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80 [PMID: 15206996]
13. Goldberg DS, Forde KA, Carbonari DM, Lewis JD, Leidl KB, Reddy KR, Haynes K, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA, Lo Re V. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 2015; 148: 1353-1361.e3 [PMID: 25733099]
14. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014; 34: 115-122 [PMID: 24879977 DOI: 10.1055/s-0034-1375953]
15. Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Giaquinto C, Picelli G, Oteri A, de Bie S, Valkhoff VE, Schuemie MJ, Mazzaglia G, Cricelli C, Rossi F, Capuano A, Sturkenboom MC. Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries. Drug Saf 2013; 36: 1007-1016 [PMID: 23591830 DOI: 10.1007/s40264-013-0045-7]
16. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 2013; 25: 825-829 [PMID: 23510965 DOI: 10.1097/ MEG.0b013e32835f6889]
17. Teschke R, Zhang L, Long H, Schwarzenboeck A, Schmidt-Taenzer W, Genthner A, Wolff A, Frenzel C, Schulze J, Eickhoff A. Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases. Ann Hepatol 2015; 14: 7-19 [PMID: 25536637]
18. Chalasani N, Björnsson E. Risk factors for idiosyncratic druginduced liver injury. Gastroenterology 2010; 138: 2246-2259 [PMID: 20394749 DOI: 10.1053/j.gastro.2010.04.001]
19. Petronijevic M, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. J Clin Pharmacol 2013; 53: 435-443 [PMID: 23440959 DOI: 10.1002/ jcph.3]
20. Hunt CM, Yuen NA, Stirnadel-Farrant HA, Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol 2014; 70: 519-526 [PMID: 25236535 DOI: 10.1016/j.yrtph.2014.09.007]
21. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34: 123-133 [PMID: 24879978 DOI: 10.1055/s-0034-1375954]
22. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388-396 [PMID: 23258593 DOI: 10.1002/hep.26208]
23. Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos 2014; 42: 744-750 [PMID: 24464804 DOI: 10.1124/ dmd.113.056267]
24. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146: 914-928 [PMID: 24389305 DOI: 10.1053/j.gastro.2013.12.032]
25. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis 2014; 34: 134-144 [PMID: 24879979 DOI: 10.1055/s-0034-1375955]
26. Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis 2013; 17: 749-767, xi [PMID: 24099029 DOI: 10.1016/j. cld.2013.07.014]
27. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49: 250-257 [PMID: 19085949 DOI: 10.1002/hep.22620]
28. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109: 950-966; quiz 967 [PMID: 24935270 DOI: 10.1038/ajg.2014.131]
29. Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014; 6: 17-32 [PMID: 24653791 DOI: 10.4254/wjh.v6.i1.17]
30. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89: 95-106 [PMID: 24388027 DOI: 10.1016/j.mayocp.2013.09.016]
31. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 2014; 34: 172-193 [PMID: 24879982 DOI: 10.1055/s-0034-1375958]
32. Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014; 6: 160-168 [PMID: 24799984 DOI: 10.4254/wjh.v6.i4.160]
33. FDA. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Available from: URL: http: //wwwfda gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090 pdf 2009
34. Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol 2015; Epub ahead of print [PMID: 25732608 DOI: 10.1016/j.clinre.2015.01.003]
35. Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug Saf 2012; 35: 1099-1117 [PMID: 23137150 DOI: 10.2165/11632970-000000000-00000]
36. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014; 100: 550-556 [PMID: 24476812 DOI: 10.1136/heartjnl-2013-305288]
37. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014; 61: 293-300 [PMID: 24681117 DOI: 10.1016/j.jhep.2014.03.026]
38. Liakoni E, Rätz Bravo AE, Terracciano L, Heim M, Krähenbühl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014; 174: 1683-1686 [PMID: 25155865 DOI: 10.1001/jamainternmed.2014.3912]
39. Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol 2015; Epub ahead of print [PMID: 25689417 DOI: 10.1111/bcp.12611]
40. Moore N, Blin P, Gulmez SE. New oral anticoagulants (NOAC) and liver injury. J Hepatol 2014; 61: 198-199 [PMID: 24837361 DOI: 10.1016/j.jhep.2014.05.010]
41. Veluswamy RR, Ward SC, Yum K, Abramovitz RB, Isola LM, Jagannath S, Parekh S. Adverse drug reaction: pomalidomide-induced liver injury. Lancet 2014; 383: 2125-2126 [PMID: 24953475 DOI: 10.1016/S0140-6736(14)61030-8]
42. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Orzechowski HD, Kreutz R, Garbe E. Flupirtine-induced liver injury--seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70: 453-459 [PMID: 24366502 DOI: 10.1007/s00228-013-1631-4]
43. Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6: 601-612 [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601]
44. Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf 2015; 14: 325-334 [PMID: 25409549 DOI: 10.1517/14740338.2015.983071]
45. Greenblatt HK, Greenblatt DJ. Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 2014; 54: 1321-1329 [PMID: 25216238 DOI: 10.1002/jcph.400]
46. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressantinduced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404-415 [PMID: 24362450 DOI: 10.1176/appi.ajp.2013.13050709]
47. Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, Sáinz M, Falomir T, Bagheri H, Herdeiro MT, Venegoni M, Montastruc JL, Carvajal A. Hepatotoxicity related to agomelatine and other new antidepressants: a case/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems. J Clin Psychopharmacol 2014; 34: 327-330 [PMID: 24561328 DOI: 10.1097/JCP.0000000000000094]
48. Gahr M, Kratzer W, Fuchs M, Connemann BJ. Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Drug Metab 2014; 15: 694-702 [PMID: 25255870]
49. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489 [PMID: 16025496]
50. Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC. Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol 2015; 13: 1328-1336.e2 [PMID: 25528012 DOI: 10.1016/j.cgh.2014.11.036]
51. Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjörnsson B, Olafsson S. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015; 13: 602-608 [PMID: 25131534 DOI: 10.1016/j.cgh.2014.07.062]
52. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014; 60: 679-686 [PMID: 24700436 DOI: 10.1002/hep.27157]
53. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399-1408 [PMID: 25043597 DOI: 10.1002/hep.27317]
54. Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology 2015; 148: 517-532.e3 [PMID: 25500423 DOI: 10.1053/ j.gastro.2014.12.004]
55. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 2014; 78: 619-629 [PMID: 25279406]
56. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, Garbe E. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol 2015; 79: 988-999 [PMID: 25444550 DOI: 10.1111/bcp.12565]
57. Ferrajolo C, Coloma PM, Verhamme KM, Schuemie MJ, de Bie S, Gini R, Herings R, Mazzaglia G, Picelli G, Giaquinto C, Scotti L, Avillach P, Pedersen L, Rossi F, Capuano A, van der Lei J, Trifiró G, Sturkenboom MC. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf 2014; 37: 99-108 [PMID: 24446276 DOI: 10.1007/s40264-013-0132-9]
58. Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, Mezi S, Cortesi E. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2014; 77: 929-938 [PMID: 23981115 DOI: 10.1111/bcp.12231]
59. Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitorsinduced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 2013; 39: 199-206 [PMID: 23099278 DOI: 10.1016/ j.ctrv.2012.09.004]
60. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36: 491-503 [PMID: 23620168 DOI: 10.1007/s40264-013-0048-4]
61. Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol 2015; 11: 231-242 [PMID: 25400226 DOI: 10.1517/17425255.2015.983075]
62. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014; 53: 773-785 [PMID: 25091053 DOI: 10.1007/s40262-014-0157-y]
63. Barbehenn E, Almashat S, Carome M, Wolfe S. Hepatotoxicity of alogliptin. Clin Pharmacokinet 2014; 53: 1055-1056 [PMID: 25336392 DOI: 10.1007/s40262-014-0199-1]
64. Scheen AJ. Alogliptin: concern about hepatotoxicity? Clin Pharmacokinet 2014; 53: 1057-1059 [PMID: 25336393 DOI: 10.1007/s40262-014-0200-z]
65. Raschi E, Poluzzi E, De Ponti F. Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretinbased therapies for the management of type 2 diabetes mellitus". Clin Pharmacokinet 2015; 54: 447-448 [PMID: 25721222 DOI: 10.1007/s40262-015-0248-4]
66. Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014; 34: 227-239 [PMID: 24879986 DOI: 10.1055/s-0034-1375962]
67. Przybylak KR, Cronin MT. In silico models for drug-induced liver injury--current status. Expert Opin Drug Metab Toxicol 2012; 8: 201-217 [PMID: 22248266 DOI: 10.1517/17425255.2012.648613]
68. Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 2014; 10: 1553-1568 [PMID: 25297626 DOI: 10.1517/17425255.2014.967680]
69. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, Masek M, Michie SA, Glenn J, Peltz G. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 2014; 11: e1001628 [PMID: 24736310 DOI: 10.1371/journal.pmed.1001628]
70. Xu D, Wu M, Nishimura S, Nishimura T, Michie SA, Zheng M, Yang Z, Yates AJ, Day JS, Hillgren KM, Takeda ST, Guan Y, Guo Y, Peltz G. Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity. J Pharmacol Exp Ther 2015; 352: 274-280 [PMID: 25424997 DOI: 10.1124/jpet.114.220798]
71. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34: 243-252 [PMID: 21332248 DOI: 10.2165/11586600-000000000-00000]
72. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gómez M, Jimenez-Perez M, Bruguera M, Prieto M, Bessone F, Hernandez N, Arrese M, Andrade RJ. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109-118.e5 [PMID: 24704526 DOI: 10.1053/j. gastro.2014.03.050]
73. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014; 147: 96-108.e4 [PMID: 24681128 DOI: 10.1053/j.gastro.2014.03.045]
74. Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology 2014; 147: 20-24 [PMID: 24880009 DOI: 10.1053/j.gastro.2014.05.027]
75. Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins PB. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf 2014; 37 Suppl 1: S57-S62 [PMID: 25352328 DOI: 10.1007/s40264-014-0186-3]
76. Vuppalanchi R, Navarro V, Vega M, Bonkovsky HL, Seeff L, Serrano J. Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. Gastroenterology 2015; 148: 480-482 [PMID: 25579757 DOI: 10.1053/j. gastro.2015.01.004]
77. Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol 2015; 6: 72 [PMID: 25954198 DOI: 10.3389/ fphar.2015.00072]
78. Holden AL, Contreras JL, John S, Nelson MR. The international serious adverse events consortium. Nat Rev Drug Discov 2014; 13: 795-796 [PMID: 25359365 DOI: 10.1038/nrd4441]
79. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16: 697-703 [PMID: 21624500 DOI: 10.1016/ j.drudis.2011.05.007]
80. Alfredsson J, Roe MT. Risks and benefits of triple oral antithrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. Drug Saf 2015; 38: 481-491 [PMID: 25829216 DOI: 10.1007/s40264-015-0286-8]
81. Layton D, Shakir SA. Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance. Drug Saf 2015; 38: 153-163 [PMID: 25564333 DOI: 10.1007/ s40264-014-0260-x]